MyNameIsJeff
Member
- Added more US domestic offers
- Added pharma products. To make this work, I assume that each of the pharma products is legitimate (i.e. not counterfeit), and that the quality of each is at the highest achievable level. This may not be true for all sources, so use at your own discretion. Nevertheless, this approach allows us to assess the best-case scenario for the cost-effectiveness of pharma GH.
- An interesting finding is that NGENLA is one of the most cost-effective pharma products for GH receptor agonism. Note that 60 mg NGENLA are equivalent to 65 IU of rHGH in terms of GH receptor agonism and therefore overall effectiveness. Calculation: (60mg / 2.77) * 3 (IU/mg) = 65 IU equivalent. Source: About NGENLA™ (somatrogon-ghla) Injection
- To keep the size manageable, some of the old promo offers have been removed. I now only show the best promo offer per product per manufacturer, and only those in the upper half of the table (since, who cares about a promo offer that is miles behind the regular pricing of competitors).

- Added pharma products. To make this work, I assume that each of the pharma products is legitimate (i.e. not counterfeit), and that the quality of each is at the highest achievable level. This may not be true for all sources, so use at your own discretion. Nevertheless, this approach allows us to assess the best-case scenario for the cost-effectiveness of pharma GH.
- An interesting finding is that NGENLA is one of the most cost-effective pharma products for GH receptor agonism. Note that 60 mg NGENLA are equivalent to 65 IU of rHGH in terms of GH receptor agonism and therefore overall effectiveness. Calculation: (60mg / 2.77) * 3 (IU/mg) = 65 IU equivalent. Source: About NGENLA™ (somatrogon-ghla) Injection
- To keep the size manageable, some of the old promo offers have been removed. I now only show the best promo offer per product per manufacturer, and only those in the upper half of the table (since, who cares about a promo offer that is miles behind the regular pricing of competitors).

Last edited:


